- Price
- $135.81
- Day
- +2.67%
- Mkt Cap
- $8.73B
- 52W Range
- $50.49 – $143.29
- Volume
- 586.0K
- Beta
- 1.79
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Bank of New York Mellon Corp lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 341,465 shares of the company's stock after selling 8,923 shares during the quarter. Bank
Read full article
Fifth Third Bancorp grew its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 3,937.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,202 shares of the company's stock after acquiring an additional 12,875 shares during the period. Fifth
Read full article
NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Read full article